This review outlines the pathophysiology and clinical characteristics of progressive fibrosing interstitial lung disease (PF-ILD) and focuses on the efficacy and safety of the antifibrotic nintedanib in patients with PF-IFD as demonstrated in the INBUILD trial.
It also provides commentary from Associate Professor Nicole Goh, respiratory physician and Director of the Interstitial Lung Disease Unit at the Austin Hospital, Melbourne and Clinical Associate Professor, faculty of Medicine at the University of Melbourne.
Please login below to download this issue (PDF)